Overview

A Study of Single-dose MY008211A in Healthy Adults

Status:
Active, not recruiting
Trial end date:
2023-06-03
Target enrollment:
Participant gender:
Summary
The trial is the first human trial. The safety, tolerability, PK and PD of MY008211A Tablets will be evaluated in healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Wuhan Createrna Science and Technology Co., Ltd